afdx 384 has been researched along with octylonium in 1 studies
Studies (afdx 384) | Trials (afdx 384) | Recent Studies (post-2010) (afdx 384) | Studies (octylonium) | Trials (octylonium) | Recent Studies (post-2010) (octylonium) |
---|---|---|---|---|---|
78 | 0 | 6 | 97 | 24 | 34 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Addison, S; Evangelista, S; Greer, S; Hernon, J; Johns, N; Johnson, I; Lewis, M; Lindqvist, S; Mackay, J; Rhodes, M; Sharp, P; Speakman, C; Stebbings, W; Tighe, R; Watson, M; Williams, M | 1 |
1 other study(ies) available for afdx 384 and octylonium
Article | Year |
---|---|
The colon-selective spasmolytic otilonium bromide inhibits muscarinic M(3) receptor-coupled calcium signals in isolated human colonic crypts.
Topics: Acetylcholine; Animals; Atropine; Calcium; Calcium Signaling; CHO Cells; Colon; Cricetinae; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Muscarinic Antagonists; Parasympatholytics; Piperidines; Pirenzepine; Quaternary Ammonium Compounds; Receptor, Muscarinic M3; Receptors, Muscarinic; Time Factors; Vasodilator Agents | 2002 |